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A b s t r a c t  
The location of the immunologic response to an allograft is not known with certainty.  
However, organized collections of T cells, B cells and antigen presenting cells have been 
found in peripheral tissue, in close proximity to organs undergoing rejection.  It is 
hypothesized that this tertiary lymphoid tissue may be a location in which activation of 
lymphocytes can occur, leading to rejection of an allograft.  We report here that in a 
splenectomized aly/aly mouse, which is devoid of secondary lymphoid organs and will 
normally fail to reject an allograft, the presence of tertiary lymphoid organs is associated 
with graft rejection.  We additionally find that tertiary lymphoid organs can act as lymph 
nodes, and can support effector and memory allograft rejection responses.  It is 
demonstrated that ectopic lymphoid tissue in aly/aly mice will support the multiplication 
and transformation of transferred naïve CD4 and CD8 T cells into cells that display 
phenotypic markers characteristic of effector and memory lymphocytes.  These results 
demonstrate that ectopic lymphoid tissue is associated with the loss of immunologic 
ignorance and is sufficient to enable graft rejection.  This suggests that allograft rejection 
may take place within ectopic lymphoid tissue, and suggests that techniques to interfere 
with the development of this tissue might offer a therapeutic approach to preserving organ 
allografts. 
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INTRODUCTION  
Background of Problem 
While organ and tissue transplantation holds great promise for the treatment of end-stage 
organ disease, immunological rejection of transplanted tissue remains a significant clinical 
challenge.  In order to stave off rejection, transplant recipients must currently commit to a 
lifetime regimen of immunosuppressive drugs.  While these pharmaceuticals greatly reduce 
the incidence and magnitude of the rejection process, their use comes with many 
drawbacks.  The drugs suppress the entire systemic immune system, leaving patients open 
to opportunistic infection and malignancies.  They are expensive, and most importantly, 
they fail to completely suppress long-term organ rejection.   
Because of these substantial drawbacks of systemic immunologic suppression, any 
mechanism that would permit the immune system to remain disinterested in a specific 
antigen, such as a grafted organ, while maintaining the system’s natural surveillance and 
disease suppression functions, would be highly desirable. 
Acute rejection of an allograft depends on the responses of activated CD4 and CD8 T 
lymphocytes.  Activation of naïve lymphocytes occurs when alloantigen is presented to a 
naïve lymphocyte by an antigen-presenting cell, along with coincident signaling through 
costimulatory receptors.  Efforts to prevent rejection currently focus primarily on 
interruption of these signaling pathways in an effort to inhibit the subsequent activation and 
clonal expansion of alloreactive lymphocytes. It also important, however, to understand the 
anatomic context in which activation occurs, because if it is possible to interrupt the sites of 
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interaction of the cells involved in the adaptive immune response, such that foreign 
antigen is not presented to naïve T cells, it may be possible to exploit immunologic 
ignorance of grafted tissue, rather than tolerance, as a long-term mechanism permitting 
graft survival.   
Immunologic Ignorance 
Immunologic ignorance is a state in which the immune system remains quiescent because it 
is unaware that a particular antigen is present.  In such a state, the immune system is not 
suppressed, but fully functional, and will freely respond to antigenic stimuli that are 
successfully presented.  However, if the mechanism of antigen presentation is disrupted, 
then the immune system will remain oblivious to the presence of alloreactive tissue.  As 
long as ignorance is preserved, foreign antigen, including transplanted tissue from 
unrelated donors, will remain free of efforts by the immune system to reject the tissue.  
However, if normal locations and mechanisms of immune stimulation are reestablished, 
ignorance will be broken, and allogeneic tissue will again be subjected to evaluation by the 
usual mechanisms of immune alloreactivity.   
Zinkernagel has posited a general “antigen-localization dose time” model for immunologic 
interactions, which proposes that the localization of antigen with respect to lymphoid tissue 
and the time of interaction are prime determinants of the pattern of reactivity towards an 
antigen(1).  Moderate quantity of antigen, newly presented to a naïve T cell by an antigen-
presenting cell in the anatomic context of secondary lymphoid tissues will initiate a 
reaction.  Antigens that do not reach lymphoid tissues, or do so in insufficient quantity or 
interact for too little time, will be ignored by the immune system. This model, when 
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applied to transplant antigens, implies that variation in the quantity or functional 
availability of tissue that facilitates interaction between antigen presenting cells and 
immunoreactive lymphocytes is a significant variable in determining the likelihood of 
reactivity.  Precise understanding of the exact location of this immunological interaction is 
therefore of crucial importance if one is to successfully develop techniques to prevent the 
loss of ignorance, thereby facilitating the long-term survival of allografts.  
The location of the alloimmune response 
Preserving immunologic ignorance by interrupting the communication lines between the 
various parts of the adaptive immune response requires knowledge of where these 
interactions take place within the immune system.  Most research to date has focused on 
the transport of antigen to secondary lymphoid tissue. 
In 1968, Barker and Billingham demonstrated that skin grafts were rejected much more 
quickly when implanted into a recipient site that allowed lymphatic outflow, compared to 
placement in a vascular bed without lymphatic drainage (2).  The presumptive mechanism 
behind this phenomenon is that secondary lymphoid tissue provides a permissive context 
for direct recognition of alloantigens that are presented by graft-derived antigen presenting 
cells to naïve T lymphocytes, which reside in these peripheral lymph nodes.  Activated T 
lymphocytes then respond swiftly against graft tissue. 
Consistent with this model, it was demonstrated in 2000 that a mouse devoid of secondary 
lymphoid tissue would indefinitely accept a vascularized allograft (3).  Because the 
lymphocytes from these mice were able to mount an effective response if transferred to 
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another animal with intact lymphoid organs, it was concluded that the inability to reject 
the allograft in the lymphoid-deficient animal was due to immunologic ignorance, 
maintained by the inability of antigen presenting cells and potentially reactive lymphocytes 
to interact.  This suggests that secondary lymphoid tissue is essential for the interaction 
between antigen-presenting cells and reactive antigen-specific lymphocytes. 
Tertiary Lymphoid Tissue 
There remains an additional possible lymphoid site for the activation of alloreactive 
lymphocytes.  In addition to the embryonically derived lymphatic system, mucosal 
lymphoid tissue and the spleen (together, the traditional secondary lymphoid tissue) there is 
evidence that ectopic lymphoid tissue located in the peripheral tissues, known as tertiary 
lymphoid tissue, is able to contribute to the development of an immune response against a 
wide array of antigens. 
Tertiary lymphoid organs (TLO) are organized collections of T cells, B cells and antigen 
presenting cells that form in peripheral tissue, usually in association with chronic 
inflammation.  This ectopic lymphoid tissue displays a wide range of anatomical 
organization, ranging from simple expression of lymphoid-related signaling molecules to 
full-fledged lymph node-like structures with characteristic high endothelial venules, 
germinal centers, and specific areas of B- and T cell localization. 
Distribution of Tertiary Lymphoid Tissue 
TLO have previously been shown to be present in multiple pathologic conditions, including 
autoimmunity, infection and neoplasia. 
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Tertiary lymphoid organs in autoimmune disease   
TLO have been observed at the site of autoimmune processes such as Sjögren’s disease, 
Graves’ and Hashimoto’s thyroiditis, and rheumatoid arthritis (4).  Thyroid tissue from 
patients with both Graves’ and Hashimoto’s disease has been noted to display lymphoid 
accumulations with high grade architecture, including high endothelial venules near 
organized T cell areas, distinct B cell follicles, and plasma cell concentrations (5).  These 
lymphoid follicles contain high levels of antibodies specific for thyroid antigens and are 
sites of high levels of recombinase gene expression (RAG1, RAG2), suggesting that 
affinity maturation of lymphocytes against thyroid antigen occurs within these TLO (6). 
The localization of leukocyte subsets within the circulation and the tissues is determined by 
the differential expression of chemokines, integrins, and other adhesion and 
communication molecules, which enable lymphocytes to enter or leave specific tissues.  
Analysis of chemokine expression can provide an indication that a particular tissue is 
actively engaged in the recruitment of a particular type of leukocyte.  The chronically 
inflamed joint in rheumatoid arthritis has been demonstrated to display elevated levels of B 
and T cell homing chemokines, such as CXCL13, CXCL12 and CCL19, constitutively, 
which suggests a mechanism for the organization of ectopic lymphoid tissue near the site of 
pathology (7).  Synovial tissue in rheumatoid arthritis displays lymphoid-like 
accumulations of CD4 T cells within the inflamed synovial membrane.  These collections 
have been demonstrated to be functional, as the germinal center-like structures in the 
synovial tissue support hypermutation and terminal B cell differentiation (8). 
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Similar structures have been found in Sjögren’s syndrome, an autoimmune disease 
characterized by autoantibody assault on salivary gland tissue.  As in the case of 
rheumatoid arthritis, ectopic expression of T and B cell chemokines (CXCL12 and 
CXCL13 respectively) and formation of germinal center-like structures has been noted 
within affected salivary tissue (9).  It has been further demonstrated that these germinal 
centers produce characteristic Anti-Ro and Anti-La autoantibodies, suggesting that local 
antibody production contributes to the pathology of the disease (10). 
Tertiary lymphoid organs in infection and neoplasia 
TLO have been noted in multiple organs during infectious challenge.  In response to 
infection or inflammation, it has been shown that germinal center-like tissue appears in the 
lungs of infected mice (11).  This lymphoid tissue is known as inducible bronchus-
associated lymphoid tissue, or iBALT.  This tissue expresses the lymphoid chemokines 
BLC (CXCL13) and SLC (CCL21), and on histologic examination, distinct T- and B cell 
areas are found within iBALT.  In transgenic mice that lack other components of the 
peripheral lymphoid system (lymph nodes, spleen, Peyer’s patches), iBALT has been 
shown to be sufficient to mount a functional immune response against viral infection, 
showing that TLO can fully support immune reactions without depending on native 
secondary lymphoid organs. 
There have been multiple findings of TLO in the context of bacterial infection.  Liver-
specific peripheral immune tissue has been noted during hepatic granulomatous infection 
with Propionibacterium actes (12).  TLO in murine small intestine are functional sites for 
the production of antigen specific IgA following bacterial challenge (13).  Vessels with 
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histologic and biochemical similarity to lymphoid tissue have been described in gastric 
mucosa in correlation with Helicobacter pylori infection, and were noted to recede with 
antibiotic eradication of the microbe (14). 
In invasive ductal carcinoma of the breast, ectopic germinal centers in intratumoral follicles 
support affinity maturation of B cells, with enhanced reactivity of follicular antibodies 
toward tumor antigens, suggesting a beneficial autoimmune response generated within 
TLO against malignant tissue (15). 
Development of Lymphoid tissue 
Lymphoid neogenesis occurring in peripheral tissue is believed to recapitulate the 
development of lymphoid tissue that takes place during organogenesis (16).  Because of the 
parallels between fetal lymphogenesis and ectopic lymphoid neogenesis, and the 
importance of the transgenic models with germ-line defects in lymphogeneic pathways, the 
development of lymph nodes during embryogenesis will be briefly reviewed. 
Fetal lymphogenesis 
In the developing fetus, lymphogenesis occurs early in organogenesis, soon after the 
development of the vasculature.  In murine development, this occurs on embryonic day 11 
when buds of endothelial cells begin to project off venous conduits, near sites of signaling 
molecules. 
Development of lymph nodes critically depends on interaction between hematopoietic 
“inducer” cells and stromal cells, which display both the adhesion molecule VCAM1 and 
the lymphotoxin-β receptor (LTβR).  Both of these cells are present in early lymph node 
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anlagen.  The inducer cells bear both the LTβR ligand LTα1β2 and the integrin α4β1 that is 
able to bind to the VCAM1 adhesion molecule on stromal cells described above.  Once 
bound to VCAM1, LTα1β2 mediated signaling of the LTβR on the stromal cell can take 
place. 
THE LYMPHOTOXIN-BETA RECEPTOR 
Signaling through the lymphotoxin-β receptor is critical to the formation of lymph nodes, 
and can be accomplished by two members of the TNF-family, the ligands LTα1β2 and 
LIGHT.  Because LIGHT deficient mice do develop lymphoid tissue, it is presumed that 
LTα1β2 plays a dominant role.  Mice deficient in lymphotoxin alpha(LTα) do not develop 
lymph nodes or Peyer’s patches (17)(18).  In such mice, treatment of pregnant mice with 
agonist antibody that is capable of stimulating the LTβR will restore lymph node 
development in offspring, thus demonstrating the critical role of LTβR in the development 
of lymph nodes (19)  Blockade of the LTβR in utero with soluble blocking antibody will 
prevent the formation of most lymph nodes; however, a subset of mucosal lymph nodes 
will still develop, indicating that the LTβR pathway is not the exclusive trigger for 
lymphogenesis (20). 
The LTβR mediates signaling through two distinct NFκB related pathways (21).  These 
pathways are relevant to this experiment because an important murine model of ignorance, 
the aly/aly mouse, involves a mutation in a component of these pathways.  In the initial 
“classical” LTβR receptor signaling pathway, LTβR ligation induces activation of an IKK 
complex, initiating a signaling pathway that results in upregulation of adhesion molecules 
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ICAM1, VCAM1 and MAdCAM-1 (22).  The increased synthesis of these adhesion 
molecules may lead to further inducer cell adherence, thereby exponentially increasing 
LTβR signaling through positive feedback from the increased population of inducer cells.  
The second “alternative” LTβR signaling pathway leads to NFκB-inducing kinase (NIK) 
activation, which triggers IKKα and subsequently induces upregulation of transcription of 
multiple chemokines that are critical for lymphoid cell homeostasis including SLC 
(CCL21), BLC (CXCL13), and ELC (CCL19) (23).  The aly/aly mouse is the result of a 
point mutation in the NIK gene, which prevents activation of the alternative LTβR 
pathway.  Because of this inhibition, the aly/aly mouse possesses neither lymph nodes nor 
Peyer’s patches, in addition to other defects including the absence of mammary glands, and 
abnormal splenic and thymic architecture (24). 
During the development of lymph nodes, other critical signaling molecules are expressed, 
including the addressins PNAd (peripheral node addressin) and MAdCAM-1(mucosal 
addressin cell adhesion molecule), as well as enzymes such as HEC-6ST, which is 
necessary to appropriately sulfate these glycoproteins (25).  The presence of these 
molecules has proved useful for the identification and localization of ectopic lymphoid 
tissues. 
Experimentally induced lymphoid neogenesis 
Mice that transgenically express ligands of the LTβR or the TNF receptor (TNFR) will 
develop inflammatory lesions at the site of expression (16).  Such lesions have been shown 
to display characteristics of organized lymphoid tissue.  RIP-LTα transgenic mice, which 
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express lymphotoxin-α under the control of the rat insulin promoter, develop chronic 
inflammatory lesions in the skin, pancreas and kidney.  Pancreatic and renal lesions have 
been shown to contain T and B lymphocytes, plasma cells, and antigen presenting cells, 
and are the site of expression of lymphoid homing chemokines such as secondary lymphoid 
chemokine (SLC) and B lymphocyte chemokine (BLC) (26).  The lesions display 
anatomically delineated areas with resident cells arranged in a manner similar to a classic 
lymph node.  Formation of these lesions is critically dependent on the presence of TNF 
receptor 1 (27).  Skin lesions in RIP-LTα transgenic mice appear histologically similar to 
the pancreatic and renal lesions, however there remains a need for further characterization 
of the contents of intradermal lesions.  Mice with transgenic expression of both LTα and 
LTβ show accumulations with even more distinct T and B cell compartmentalization and 
prominent follicular dendritic cell networks within ectopic lymphoid tissue (25).  
Furthermore, expression of characteristic lymph node molecules such as PNAd and HEC-
6ST as well as lymphoid chemokines can be observed within the lesions. 
Tertiary lymphoid organs and the alloimmune response   
To date, the functional capacity of TLO in allograft rejection has not been conclusively 
demonstrated.  It has previously been shown that an immune response to an allogeneic 
vascularized transplant is dependent on the presence of secondary lymphoid organs (3).  
This paper demonstrated that in a splenectomized aly/aly model, devoid of all secondary 
lymphoid tissue, vascularized cardiac allografts were accepted indefinitely.  It was shown 
that despite the failure to reject the allograft, the host immune cells remained competent, 
and were able to mediate rejection either if lymphocytes were transferred to recipients with 
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intact lymphoid structures or if exogenously activated T cells were transferred to 
transplant recipients. Because the acceptance of the grafts occurred without 
immunosuppression, and coexisted with an otherwise functional immune system, 
immunologic ignorance of the allograft was presumably a consequence of the absence of 
secondary lymphoid tissue. 
Lymph node-related adhesion molecules have been noted to be present at the sites of 
allograft rejection.  In a study of human post-transplant endomyocardial biopsy samples, 
Toppila et al. demonstrate an increased level of expression of L-selectin ligands selectively 
during the acute rejection episodes (28).  This ligand, which mediates lymphocyte 
extravasation into peripheral tissue, was not present in the absence of rejection, and the 
magnitude of its expression was correlated with the degree of rejection.  Kirveskari, et al, 
similarly demonstrate the upregulation of L-selectin ligands on kidney endothelial tissue 
solely during episodes of acute rejection, also with a magnitude of expression correlated 
with the degree of rejection (29).  The presence of this lymphocyte ligand suggests a 
mechanism for the incursion of lymphocytes into graft tissue, thereby facilitating rejection. 
The possibility that there is an additional site of interaction between APCs and naïve T 
cells during graft rejection follows from the identification of organized lymphoid structures 
within murine cardiac allografts undergoing chronic rejection (30).  In this study, 
lymphoneogenesis was invariably associated with rejection: all recipients with either 
tertiary lymphoid organs with discrete T and B cell zones and PNAd positive high 
endothelial venules(HEV), or only less organized PNAd+ HEV, were found to have some 
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degree of rejection.  Of the allografts with chronic rejection, 78% had identifiable 
lymphoid neogenesis.  Allografts or syngeneic grafts that were not undergoing rejection did 
not have evidence of lymphoid neogenesis. 
Recently, similar findings were found in human cardiac and kidney tissues that were 
explanted following chronic rejection.  In all rejected organs, but not in control explants, 
germinal center-like structures were found that contained T lymphocytes and areas of 
proliferating B cells in close proximity to follicular dendritic cells (31).  In a rodent 
transplant model by the same authors, areas of TLO found in the vascular endothelium of 
transplanted aortic tissue displayed HEV phenotypic markers and organized lymphoid 
anatomy.  The cell population within the TLO changed over time from a CD8 T cell 
infiltrate consistent with an acute cytotoxic response to a CD4 T cell population that 
displayed cell surface markers characteristic of helper T cells that assist resident B cells. 
This close linkage between allograft rejection and the presence of ectopic lymphoid tissue 
suggests that there is a functional role for tertiary lymphoid tissue in the alloimmune 
response.  The current study creates an experimental model to prospectively test the 
relationship between ectopic lymphoid tissue and transplant rejection. 
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STATEMENT OF PURPOSE, SPECIFIC HYPOTHESIS  
AND SPECIFIC AIMS OF THE THESIS  
The review above suggests that ectopic lymphoid tissue may play a role in the loss of 
immunologic ignorance of an allograft, and thus may be a site of interaction between 
antigen presenting cells and T cells that is critical for allograft rejection.  Demonstrating 
that the presence of ectopic lymphoid tissue is associated with graft rejection, the absence 
of ectopic lymphoid tissue is associated with immunologic ignorance, and the transfer of 
ectopic lymphoid tissue can reconstitute an alloimmune response would, in a manner 
consistent with Koch’s postulates, strongly suggest a functional role for ectopic lymphoid 
tissue in the rejection of tissue allografts.  Understanding the capacity of specific tissue to 
play a contributory role in allograft rejection may prove significant in developing therapies 
designed to prevent rejection of transplanted organs and tissue. 
The specific hypothesis of this thesis is that ectopic lymphoid tissue in transplanted skin 
acts as functional lymphoid tissue and is sufficient to break immunologic ignorance.  This 
thesis aims to prove this hypothesis by demonstrating the loss of immunologic ignorance 
and the development of specific lymph node function following the introduction of 
intragraft TLO into a transplant model, and by assessing the growth and transformation of 
T cells in mice with transplants containing tertiary lymphoid tissue. 
To explore the functional capacity of tertiary lymphoid organs in supporting the 
alloimmune response and the breakage of immunological ignorance, we compare here the 
survival of wildtype allogeneic skin grafts (allografts), syngeneic RIP-LTα skin grafts that 
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have ectopic lymphoid tissue transgenically expressed in the skin, and allogeneic RIP-
LTα skin grafts, also with dermal ectopic lymphoid tissue, after transplantation to 
splenectomized aly/aly (aly/aly-spleen) mice without secondary lymphoid organs (figure 
1).  Recipient Donor 
WT 
F1  
WT
aly/aly
B6allo 
LTαLTα 
F1 
aly/aly 
B6allo 
LTα aly/aly
B6
LTα 
B6 syn 
Graft 
 
Figure 1  The experimental groups.  Donor tissue is either 
allogeneic wild-type, syngeneic LTα transgenic or allogeneic 
LTα transgenic skin.  All recipients are splenectomized aly/aly B6 
mice. 
It is expected that splenectomized aly/aly mice will remain ignorant of an allograft, 
consistent with prior published research.  It is the first aim of this thesis to test whether the 
presence of ectopic lymphoid tissue in an allograft will be sufficient to break immunologic 
ignorance in this host and will lead to rejection of allografts that would otherwise remain 
accepted.  Control syngeneic transplants, with or without intragraft TLO, should show no 
rejection. 
If ectopic lymphoid organs actually function as lymph nodes, then it should be 
demonstrable that the presence of this tissue permits the development of the effector and 
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memory components of an allograft rejection response.  The second aim of this thesis is 
to assess the response of a splenectomized aly/aly mouse to an allogeneic skin graft 
following simultaneous transplantation of allogeneic RIP-LTα skin, prior transplantation of 
allogeneic RIP-LTα skin, or prior transplantation of syngeneic RIP-LTα skin.  As 
mentioned above, the splenectomized aly/aly mouse has been shown to accept allografts 
indefinitely, without developing an effector or memory response.  If tertiary lymphoid 
tissue present in the RIP-LTα skin does indeed function as a lymph node, then one would 
expect to observe the establishment of an allospecific effector T cell response at the time of 
RIP-LTα skin transplant and generation of memory T cells, which are able to mediate the 
rejection of subsequent transplants. 
The third aim of this thesis is to assess and quantify the actual development of T cells with 
effector and memory phenotypes in otherwise lymphoid-organ free mice that receive a 
transplant of allogeneic TLO-containing skin.  If the hypothesis is true, then one should be 
able to transfer congenic naïve lymphocytes to aly/aly mice, and, following an allogeneic 
TLO-containing transplant, reharvest the same lymphocytes and observe an increase in 
expression of markers of effector and memory phenotypes on these cells. 
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METHODS 
Mice:  Wildtype (wt) C57BL/6 (B6, Thy1.2, H-2b), B6.PL-Thy1a/Cy (B6.1.1, Thy1.1, H-
2b), and CB6F1/J (H-2d/b) mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME).  alymphoplasia (aly/aly) mice (Map3k14-/-, Thy1.2, H-2b), were purchased from 
CLEA Japan (Osaka, Japan) and bred under specific pathogen free conditions.  A RIP-LTα 
mouse colony (B6, Thy1.2, H-2b) was originally obtained from Nancy Ruddle (Yale 
University) and maintained at the Yale Animal Resource Center.  RIP-LTα (B6, Thy1.2, 
H-2b) were crossed with BALB/cJ (Thy1.2, H-2d) to generate RIP-LTα F1(CB6F1/J, H-
2b/d) mice. 
Surgical Procedures:   
SPLENECTOMY:  
Splenectomy was performed under general anesthesia via a subcostal incision at least 1 
week prior to transplant procedure.  Completeness of splenectomy was verified post-
mortem in every mouse.   
SKIN TRANSPLANTATION: 
Full thickness skin transplantation was performed as follows.  The transplant was 
performed using general anesthesia.  Abdominal skin, free of nevi or scarring, from donor 
mice was harvested and subcutaneous layers removed by gentle scraping underneath a cold 
saline bath.  Recipient mice were 8-12 week old B6 aly/aly splenectomized mice.  A 1.5-
3.0 cm2 graft bed was prepared on the dorsal flank of the recipient by excision of native 
skin.  Donor skin was trimmed to fit the prepared bed, placed in situ and secured with skin 
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staples and bandages for seven days.  Mice received acetaminophen in their drinking 
water for 3 days postoperatively for analgesia.  Graft viability was monitored daily for the 
first seven days, after which grafts were monitored every other day.  Rejection was defined 
as > 90% graft necrosis.  Acceptance was defined as complete healing of the graft with 
evidence of hair growth. 
Lymphocyte isolation and characterization 
ISOLATION AND ADOPTIVE TRANSFER OF NAÏVE T CELLS:  
Spleen and lymph node cells were harvested from Thy1.1+ B6 mice to obtain naïve T cells.  
Harvested cells were enriched for T cells using Nylon Wool Fiber Columns (Polysciences, 
Inc., Warrington, PA).  Nylon wool purified T cells were then labeled with fluorochrome 
tagged antibodies against CD4, CD8 and CD44.  These cells were sorted for naive 
CD4+CD44lo and CD8+CD44lo populations (> 98% purity) using a FACS Aria high-speed 
cell sorter.   
Sorted naive CD4 or CD8 T cells (Thy1.1, H-2b) were injected intravenously into the tail 
vein of splenectomized aly/aly (aly/aly-spleen, Thy1.2, H-2b) recipients three days 
following skin transplantation.  Adoptive hosts received 5 x 106 sorted cells. 
CELL HARVEST AFTER ADOPTIVE TRANSFER:   
Mice were perfused with heparin (100 U/ml) at the time of sacrifice.  Blood was removed 
by cardiac puncture and erythrocytes were lysed with pure water.  The liver was perfused 
via the portal vein with 50 U/ml collagenase IV solution (Worthington Biochemical, 
Lakewood, NJ), removed and passed through a 70 µm strainer.  The tissue suspension was 
incubated at 37ºC with 50 U/ml collagenase IV in RPMI 1640 plus 5% FCS for 30 
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minutes.  Lymphocytes were then separated on a 25% Optiprep gradient (Accurate 
Chemical and Scientific Corp., Westbury, NY).  Lungs were perfused with PBS via right 
ventricular cannulation, removed, finely macerated and incubated at 37ºC in 50 U/ml 
collagenase IV solution for 60 minutes.  The digested tissue was passed through a 100µm 
strainer followed by centrifugation and RBC lysis.  To obtain bone marrow cells, the femur 
and tibia were flushed with PBS and the cell suspension was centrifuged followed by RBC 
lysis.  The skin was harvested, minced and digested at 37ºC for 2 hours in a solution 
containing 2.7mg/ml collagenase, 1mg/ml DNAse, 0.25mg/ml hyaluronidase.  The 
digested tissue was passed through a 100µm strainer. 
FLOW CYTOMETRY STAINING: 
Flow cytometry was performed to phenotype naïve, effector and memory lymphocytes and 
to isolate congenic (Thy1.1+) lymphocytes prior to and following adoptive transfer.  
Fluorochrome-conjugated antibodies were purchased from BD Pharmingen (San Diego, 
CA), eBioscience (San Diego, CA) or SouthernBiotech, (Birmingham, AL).  Antibodies 
were against CD4 (RM4-5), CD8a (53-6.7), CD44 (Pgp-1), CD62L (MEL-14), and 
CD90.1 (OX-7) moieties.  Flow cytometry was performed was done on FACS Aria or 
LSRII analyzers (BD Biosciences).  Data were analyzed using FlowJo software (Tree Star, 
Inc., Ashland, OR). 
IN VIVO PROLIFERATION ASSAY 
Sorted Thy1.1+ CD4 and CD8 effector or memory T cells were labeled with CFSE 
(Molecular Probes, Eugene, OR) for 10 minutes at 37ºC, washed and adoptively transferred 
to either aly/aly-spleen or wt recipients (Thy1.2).  Lymphocytes were harvested 15 or 60 
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days later from lymphoid and non-lymphoid tissues according to the protocol described 
above.  Thy1.1+ lymphocytes were isolated by flow cytometry and the extent of cell 
proliferation was measured by CFSE dilution in the transferred cell population.  
Delineation of work 
The design and implementation of this research depended greatly on a team with diverse 
strengths, talents and experience.  Preliminary research and alternative experimental 
strategies were investigated by Fadi Lakkis, Zenhua Dai, Michael Reel and Isam Nasr.  
Experimental methodology was designed by Fadi Lakkis, Isam Nasr and Michael Reel.  
Murine surgery was performed by Isam Nasr and Michael Reel.  Graft survival was 
monitored by Isam Nasr.  Isam Nasr and Michael Reel accomplished lymphocyte 
harvesting, with technical assistance provided by Lakkis Lab members.  Flow cytometry 
was performed primarily by Martin Oberbarnscheidt.  Statistical analysis was performed by 
Isam Nasr and Michael Reel.  Preparation of figures to incorporate graphic elements 
constructed by Isam Nasr. 
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RESULTS 
F i n d i n g  1 :  T e r t i a r y  L y m p h o i d  O r g a n s  a r e  a s s o c i a t e d  
w i t h  g r a f t  r e j e c t i o n  
It has previously been demonstrated that a splenectomized aly/aly mouse will indefinitely 
accept a vascularized allograft (3), where it was found that the acceptance was due to 
immunologic ignorance of the graft.  To explore the hypothesis that tertiary lymphoid 
tissue is sufficient to break such immunologic ignorance, it is necessary to show that in an 
otherwise ignorant model, the singular addition of tertiary lymphoid tissue leads to 
rejection.  In order to demonstrate this, skin transplants from transgenic RIP-LTα mice 
were grafted onto aly/aly splenectomized mice.  RIP-LTα mice express lymphotoxin-α 
under control of the rat insulin promoter, and display markedly increased expression of 
LTα in the pancreas, skin and the kidney.  The expression of LTα in these areas leads to 
the local development of ectopic lymphoid tissue, similar in nature to that found in a lymph 
node, and notably similar to the tertiary lymphoid tissue found at the sites of allograft 
rejection in wild-type animals receiving vascularized allografts.  Transplant of allogeneic 
RIP-LTα skin accomplishes both the establishment of ectopic lymphoid tissue as well as 
the implantation of antigenic tissue.  Transplantation of syngeneic LTα-expressing donor 
skin is used to control for inflammatory stimuli occurring as a consequence of either the 
surgical transplant procedure or the expression of LTα. 
Three different experimental skin transplant conditions were examined.  In all cases, skin 
transplant recipients were splenectomized aly/aly B6 mice.  In case 1, the donor mouse was 
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a wild-type F1 generation BALB/c x B6 mouse, allogeneic to the B6 recipient.  
Consistent with previously reported research(3), all six aly/aly recipients indefinitely 
accepted allogeneic skin transplants.  In case 2, the donor was a syngeneic B6 RIP-LTα 
transgenic mouse, which expressed LTα in the skin, including skin used for transplant.  
This syngeneic transplant was also accepted indefinitely (n = 6).  Case 3 incorporated an 
allogeneic, F1 generation BALB/c x B6 transgenic RIP-LTα mouse as the donor.  When 
skin from this donor, which contains tertiary lymphoid organs, was transplanted onto a B6 
aly/aly recipient, the skin was rejected in a median of 18 days (n = 12) (figure 2). 
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Figure 2  Differential survival of allografts containing tertiary 
lymphoid organs.  Allogeneic wild-type skin and syngeneic LTα-
expressing skin transplants are accepted indefinitely (n=6).  
Allogeneic skin expressing LTα rejects after a median of 18 days 
(n=12). 
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F i n d i n g  2 :  T e r t i a r y  L y m p h o i d  O r g a n s  c a n  f u n c t i o n  
a s  a  l y m p h  n o d e ,  a n d  c a n  e n a b l e  e f f e c t o r  a n d  
m e m o r y  a l l o g r a f t  r e j e c t i o n  r e s p o n s e s  
The alloimmune response occurs in two phases.  At the time of a transplant, naïve 
allospecific T cells that encounter antigen presenting cells bearing alloantigen receive 
costimulatory signals and become activated T cells.  Clonal expansion of these activated T 
cells occurs, developing an effector response that may lead to the rejection of the allograft.  
Following the effector response, there is a dramatic contraction of reactive lymphocytes, 
during which the vast majority of the expanded reactive cell population undergo apoptosis.  
At the conclusion of this process, a select number of reactive cells remain in the circulation 
as memory T cells, which are able to mount a swift response in the periphery if antigen is 
encountered at a later time.   
In the context of immunologic ignorance, however, neither the effector, nor memory 
response occurs, leading to acceptance of alloreactive tissue.  One such cause of ignorance 
is a failure of antigen presenting cells to present antigen to naïve alloreactive lymphocytes.  
It is theorized that the immunologic ignorance of a splenectomized aly/aly mouse is a 
consequence of the lack of secondary lymphoid tissue, leading to a failure of interaction 
between antigen presenting cells and T lymphocytes.  If this hypothesis is true, then 
transplanting tissue containing ectopic lymphoid tissue should be presumed to supply such 
a meeting site, and should be expected to permit rejection of allogeneic tissue. 
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To examine the ability of ectopic lymphoid tissue to permit an effector alloimmune 
response, a recipient splenectomized aly/aly mouse simultaneously receives two skin 
transplants.  One graft comes from a wild-type F1 BALB/c x B6 mouse, which is 
allogeneic to the B6 aly/aly.  As mentioned above, as a stand-alone transplant, this graft 
would normally be accepted indefinitely.  The second graft, placed on the opposite flank of 
the recipient in the same surgical procedure, comes from an allogeneic F1 BALB/c x B6 
RIP-LTα transgenic mouse.  When this operation was performed on six recipients, both 
grafts were rejected in all animals.  The median graft survival time was 52 days for the wt 
graft and 53 days for the F1 RIP-LTα graft (figure 3).  Thus, the presence of a LTα 
expressing allograft precipitated the rejection of an otherwise ignored allograft. 
Surprisingly, the time to rejection was considerably longer when simultaneous transplants 
were performed (figure 3) than when a single transgenic transplant was performed (figure 
2).  Reasons for this delay in rejection are unclear, but may possibly be related to the 
aggregate quantity of grafted tissue that is rejected. 
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Figure 3  TLO permit generation of effector T cells.  When LTα 
skin and wt allogeneic skin are simultaneously transplanted, the 
LTα skin allows the rejection of both grafts 
To examine the ability of tertiary lymphoid tissue to spur a memory alloimmune response, 
6 aly/aly recipients were given asynchronous allogeneic skin transplants.  Initially, 
allogeneic grafts from F1 BALB/c x B6 RIP-LTα mice were placed, with rejection 
occurring shortly after (MST 21 days), consistent with the first experimental finding 
described above (figure 4).  50 days later, after the graft tissue had necrosed and been 
replaced by scar, a second transplant was performed, using wild-type allogeneic F1 
BALB/c x B6 skin.  Despite the lack of secondary or tertiary lymphoid tissue in this twice-
transplanted aly/aly recipient, the second graft was also rejected, with a median survival 
time of 17 days, thus suggesting that antigen specific memory T cells that had been 
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generated during the initial transplant were still circulating and retained the functional 
capacity to reject subsequent allograft tissue.  
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Figure 4  TLO permit generation of memory T cells.  When 
allogeneic LTα skin is transplanted and allowed to reject, 
subsequent wt allogeneic grafts are rejected, rather than accepted 
as in Fig. 2. 
In the final demonstration of the functional capacity of ectopic lymphoid tissue, six 
splenectomized aly/aly recipient mice again receive two asynchronous transplants.  In this 
case, the initial transplant comes from a syngeneic B6 RIP-LTα donor.  As in the control 
for the first experiment (figure 2), the syngeneic transplant is accepted, demonstrating again 
that RIP-LTα does not independently trigger graft rejection (figure 5).  With an accepted 
syngeneic skin graft remaining in place, the animal receives a second, wild-type allogeneic 
F1 BALB/c x B6 skin graft on the opposite flank.  The initial graft remains undisturbed.  In 
this case, the new wild-type allograft is no longer accepted by the aly/aly recipient, but is 
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instead rejected in a median of 31 days, suggesting a functional role for the ectopic 
lymphoid tissue located in the syngeneic graft on the contralateral flank of the recipient.  
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Figure 5.  TLO function as a lymph node.  Syngeneic LTα skin is 
transplanted and allowed to heal in.  Subsequent grafts of 
allogeneic wild type skin are  now rejected (n=6).  
 
F i n d i n g  3 :  T L O  p e r m i t  d e v e l o p m e n t  a n d  
m u l t i p l i c a t i o n  o f  T  c e l l s  t h a t  a c q u i r e  e f f e c t o r  a n d  
m e m o r y  p h e n o t y p e s  
The preceding findings demonstrate on a macroscopic scale the tolerance-breaking effects 
of tertiary lymphoid organs in transplantation and demonstrate a tight correlation between 
the presence of ectopic lymphoid tissue and the rejection of an allograft. The third 
component to this thesis demonstrates on a cellular scale the change in the phenotype of T 
lymphocytes that occurs as a result of the presence of tertiary lymphoid organs. 
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If tertiary lymphoid organs act as lymph nodes then they must be able to permit the 
activation of naive lymphocytes and the development of T cells with effector and memory 
phenotypes.  To assess whether tertiary lymphoid tissue could activate lymphocytes, naive 
T lymphocytes (CD44low) were harvested from Thy1.1+ mice.  These lymphocytes are 
otherwise identical to lymphocytes from Thy1.2+ wild-type mice, but can be specifically 
identified by the Thy1.1 antigen expressed on T cells. Experimental subjects were 
splenectomized aly/aly B6 mice that had three days previously received a skin transplant 
from an allogeneic F1 BALB/c x B6 RIP-LTα expressing mouse.  Control animals were 
aly/aly splenectomized B6 mice that received allogeneic BALB/c x B6 wild-type skin or 
syngeneic B6 RIP-LTα skin.  In each lymphocyte transfer, 5 million Thy 1.1+ lymphocytes 
were injected into the tail vein of the recipient mouse. 
Recipients were divided into two groups based on the timing of the lymphocyte harvest.  
Lymphocytes from the first group were harvested at 15 days post-transfer in order to assess 
the development of effector T lymphocytes.  Lymphocytes from the second group were 
harvested at 60 days, at which point the effector response would have been concluded, and 
lymphocyte levels returned to baseline, leaving only memory antigen-specific T 
lymphocytes. 
At each harvest date, lymphocytes were retrieved from skin, lung, liver, bone marrow, and 
peripheral blood.  Thy 1.1+ CD4 and CD8 T lymphocytes were isolated via flow cytometry, 
and the population was stratified based on expression of CD44 and CD62L, markers of T 
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lymphocyte activation.  Lymphocytes were recoverable in small but identifiable 
quantities from all locations. 
In experimental animals transplanted with allogeneic RIP-LTα skin, when harvested at the 
15 day time point, Thy 1.1  lymphocytes displayed an increase in expression of CD44, a 
decrease in CD62L expression, and significant dilution of intracellular CFSE, consistent 
with expansion of the Thy 1.1  cell population and transformation from a naïve to an 
effector phenotype (figure 6).  Control animals were transplanted with syngeneic RIP-LTα 
grafts.  Thy 1.1  lymphocytes were recovered in only very minimal quantity.  
+
+
+ CFSE 
staining did not reflect rounds of cell division, and CD62L or CD44 expression did not 
demonstrate transformation of the naïve transferred cells into effector or memory 
lymphocyte phenotypes.  Thy 1.1+ lymphocytes were not recoverable from recipients of 
wild-type non-transgenic grafts, despite identical harvest techniques, suggesting that the 
absence of lymphoid tissue failed to permit survival or expansion of the transferred 
lymphocytes 
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Figure 6. Generation of effector CD8 T cells in recipients of allogeneic LTα expressing grafts.  Thy 1.1+ transplanted T 
cells 15 days after injection show multiplication (by dilution of CFSE), an increase in CD44 and a decrease in CD62L 
expression, consistent with an effector phenotype.  Control recipients, who received syngeneic LTα expressing grafts, 
show negligible expansion or phenotypic change.  
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When harvested at the 60 day time point, transferred Thy 1.1+ lymphocytes harvested 
from liver specimens demonstrate an increase in expression of both CD62L and CD44, 
consistent with a transformation from a naïve phenotype to a central memory phenotype 
(figure 7).  There is a single CD62L peak, consistent with the apoptotic elimination of the 
effector phenotype seen at the 15 day harvest point. 
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Figure. 7. Generation of memory CD8 T cells.  Thy 1.1+ cells are 
still able to be harvested from liver specimen 60 days after 
injection, and show phenotype consistent with memory T cells.  
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DISCUSSION 
This study demonstrates that rejection of an allograft in a mouse devoid of secondary 
lymphoid tissue occurs if there is simultaneous transplantation of ectopic lymphoid tissue 
as well as alloantigen.  Immunogenic effects of inflammation related to the simple presence 
of the RIP-LTα transgene were controlled for by the inclusion of syngeneic transplants.  
These syngeneic grafts were not rejected, although they contained TLO.  Thus, differential 
graft survival in mice that receive allogeneic transplants from RIP-LTα donors must be a 
function of the additional TLO. 
We further characterized the functionality of this TLO by analyzing the differential ability 
of the tissue to support the development of effector and memory adaptive immune 
responses.  When present, TLO were sufficient to endow a previously immunologically 
quiescent mouse with an operational rejection response, demonstrating the presence of 
effector T lymphocytes.  Ectopic TLO also supported a delayed rejection capacity, 
consistent with the development of memory T cells.  Lastly, we found that TLO provided 
an aly/aly mouse with a newfound ability to reject anatomically distant foreign tissue, 
demonstrating the ability of the ectopic tissue to support a systemic immune response. 
These functional correlations were explored on the cellular level by the identification and 
quantitation of specific T lymphocytes with phenotypes characteristic of effector and 
memory T cells.  CD62L is a selectin that facilitates, and is required for, lymphocyte 
entrance into in lymph nodes, by binding glycoproteins such as GlyCAM-1 or MAdCAM-1 
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on the endothelium of lymph node high endothelial venules.  These glycoproteins are 
collectively referred to as peripheral node addressins (PNAd).  CD62L is expressed on 
naïve lymphocytes, enabling their entry into lymph nodes to survey incoming APCs for 
activating antigen.  If a T cell becomes activated, CD62L is downregulated, enabling egress 
from the lymph node into the circulation, for eventual traffic into a target organ where 
effector activity may take place.  CD44 is another differential marker of activated T cells.  
The transition from CD62Lhigh to CD62Llow and from CD44- to CD44+ observed here in 
mice receiving LTα expressing transplants is consistent with a loss of naïve phenotype for 
the transferred Thy1.1+ lymphocytes.  The dilution of CFSE is consistent with successive 
rounds of cellular division occurring in this cell population.  Both of these events occurred 
only in those mice that received ectopic TLO, suggesting that the transplanted TLO was 
capable of providing a location in which this transformation could take place. 
Our experiments confirm that TLO are sufficient to break immunologic ignorance, and 
demonstrate macroscopic and microscopic evidence of lymphocyte activation, allograft 
rejection and the formation of immunologic memory in the presence of TLO.  These results 
are consistent with prior research that demonstrated an inability of mice devoid of 
secondary lymphoid tissue to reject allogeneic grafts (3).  Interpretation of this prior 
research had been made more complicated following reports by other groups who found 
that in different models of mice without secondary lymphoid tissue, lymphotoxin-α or 
LTβR knockout mice, rejection of cardiac and skin tissue was delayed, rather than 
abrogated (32).  Differences in the specific model used for as the lymphoid tissue-deficient 
model have been suggested to underlie the different conclusions of the two groups 
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regarding the necessity of secondary lymphoid tissue for an allograft response.  
Lymphocytes from aly/aly mice have previously been reported to display defects in homing 
to gastric-associated lymphoid tissue (33), suggesting that perhaps aly/aly lymphocytes 
have an inherently poor ability to enter ectopic lymphoid tissue.  However, the results 
described herein suggest that the small amount of ectopic lymphoid tissue accompanying 
the allograft is traversable by recipient lymphocytes, as its presence correlates with 
rejection and the development of effector and memory lymphocyte phenotypes. 
Alternative explanations for the differential rejection behavior following transplant of RIP-
LTα ectopic lymphoid tissue are constrained by the failure of the control syngeneic RIP-
LTα tissue to be rejected, and its ability to support rejection of foreign tissue.  If there 
existed a factor inherent to RIP-LTα expression that is capable of inducing extralymphatic 
activation of recipient lymphocytes, then one would expect this factor to have induced 
rejection following a syngeneic RIP-LTα transplant.  The absence of such syngeneic 
rejection supports the determination that it is the presence of the lymphoid tissue itself that 
endows the ability to reject allogeneic tissue. 
Prior research has not specifically characterized the cellular components of the skin lesions 
found in RIP-LTα transgenic mice.  While these lesions appear to have histological 
characteristics of lymphoid tissue, and are the sites of expression of lymphoid 
glycoproteins such as PNAd (unpublished data), in vivo demonstration of the lymphoid 
functionality of these accumulations has not been previously published.  The evidence 
presented herein constitutes a functional demonstration of the lymph node-like abilities of 
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RIP-LTα skin.  When transgenic RIP-LTα skin, containing the characteristic lymphoid 
structures, is transplanted, it empirically performs as a lymph node, which is consistent 
with its classification as functional tertiary lymphoid tissue. 
Our results are consistent with prior research that has demonstrated that lymphoid tissue is 
found near the site of allografts undergoing rejection. Within the framework of 
Zinkernagel’s localization-dose-time model of immunologic function, the formation of 
ectopic lymphoid tissue could be considered an additional mechanism for fostering the 
interaction between lymphoid-resident cells and APCs.  Establishment of lymphoid tissue 
close to the site of antigen complements the more commonly appreciated traffic of antigen 
toward lymphoid tissue. The placement of lymphoid tissue close to the site of an allograft 
enhances the likelihood of an immunologic response, thereby leading to observed increased 
frequency of rejection when this tissue is present.  This is also consistent with the presence 
of tertiary lymphoid tissue in close proximity to autoimmune activity. When lymphoid 
tissue is brought closer to antigens that normally would not be recognized by the immune 
system, ignorance is more likely to be broken, facilitating autoimmune response against 
normally non-immunogenic self targets. 
Combined with knowledge of the pathways leading to lymphoid tissue development, these 
findings suggest therapeutic benefit from interventions designed to enhance or inhibit the 
development of tertiary lymphoid organs, in an effort to augment or suppress interaction of 
antigen-presentation to reactive lymphocytes.  If local ectopic lymphoid tissue facilitates 
the development of autoimmune pathology, then interruption of lymphoid signaling 
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pathways underlying the growth and organization of ectopic tissue may be expected to 
lead to reduction of self-recognition and restraint of autoimmune assault.  Such techniques 
have been attempted in murine models of autoimmune disease including colitis (34)(35), 
arthritis (36), and type 1 diabetes mellitus (IDDM) (37).  In the case of arthritis and colitis, 
injection of lymphotoxin-β receptor specific immunoglobulin fusion protein (LTβR Ig) 
markedly reduces inflammation and physical symptoms in collagen-induced arthritis and 
multiple models of experimentally induced colitis.  In IDDM, injection of LTβR Ig 
prevented the usual onset of diabetes in non-obese diabetic (NOD) mice, and was able to 
reverse islet destruction occurring in late stage autoimmune IDDM.  Histologic analysis of 
pancreata from LTβR-Ig treated mice revealed marked decrease in the prevalence of 
lymphoid structures, suggesting that in this experiment, local lymphoid tissue played a role 
in the disease-causing immunologic response to the nearby islet tissue. 
Not all such enhanced antigen recognition may be detrimental. It has been demonstrated 
that transgenic mice that are deficient in peripheral lymphoid tissue, yet express ectopic 
lymphoid tissue in the lung (iBALT) in response to an infectious challenge, are able to 
clear infection with a lesser degree of inflammation and damage to host tissue than wild-
type mice (11). Many solid tumors display antigens that are distinct from normal tissue 
proteins, yet the immune system fails to respond and mount an attack against these tissues.  
It has been demonstrated that the cause of this failure to respond is immunologic ignorance 
of the tumor antigens, due to a lack of presentation of antigen to lymphocytes.  If ignorance 
is broken, cytotoxic immune responses are actually quite effective in eliminating tumor 
tissue (38).  In an early demonstration of possible therapeutic use of ectopic lymphoid 
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tissue, it has been demonstrated that if lymphotoxin-α is targeted to malignant tissue, the 
resultant development of ectopic lymphoid tissue allows an improved T lymphocyte 
response and, in murine models, has resulted in the complete eradication of pulmonary 
tumors (39). 
Another potential route to inducing tolerance in autoimmune disease or transplantation is 
the development of a mechanism to target regulatory or suppressor T cells to ectopic 
lymphoid organs, thus exerting a local inhibitory effect without requiring systemic 
immunosuppression.  In a murine model of cardiac allograft tolerance, regulatory T cells 
(CD4+CD25+CD44highCD62Lhigh) were identified in peripheral lymph nodes of allograft 
recipients made tolerant by either of two different tolerogenic regimens.  Suppression of 
lymph node homing by lymphocytes, induced by injection of anti-CD62L, prevented 
regulatory T cell residence in lymph nodes and abrogated this induced tolerance.  When 
lymphocyte egress from lymph nodes was restricted by administration of FTY720, 
regulatory T cell residency in peripheral lymph nodes and allograft tolerance were restored 
(40).  In a separate skin transplant assessment of regulatory T cell activity, transferred 
CD4+CD25+ cells were noted to attenuate proliferation of graft-specific effector cells, with 
marked reduction in CD4 replication occurring in draining lymph nodes (41). These studies 
suggest that in addition to enabling allograft rejection, lymph nodes are the site for the 
tolerance-promoting action of regulatory T cells, and that attention should be paid to both 
regulatory as well as effector T cells in determining the net effect that tertiary lymphoid 
organs may have upon target tissue. 
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There remain questions about the identity of the specific cells that prompt the induction 
of ectopic lymphoid tissue.  Although multiple studies have confirmed the necessity of 
signaling through the NF-κB pathway, and in many cases the LTβR, in the development of 
both classic secondary lymphoid tissue as well as TLO, the source of the initiating cell 
remains unclear (42).  Hematopoietic CD4+CD3-IL-7Rαhi cells have been demonstrated to 
play a role in the embryonic development of lymph nodes and Peyer’s patches, where they 
have been noted to chemotax toward the chemokines ELC, SLC and BLC (CXCL13) (43). 
Signaling through the IL-7Rα on these cells results in upregulation of LTα1β2, suggesting a 
role as an inducer cell, activating the lymphogeneic pathways described earlier.  In a 
connection to ectopic lymphoneogenesis, it has been shown that the pancreatic tissue in 
transgenic mice expressing a RIP-CXCL13 transgene contains a significant population of 
CD4+CD3-IL-7Rαhi cells, suggesting that these cells may play a role in the formation of 
ectopic, as well as native, lymphoid tissue(44), however details of this pathway are yet to 
be fully elucidated. 
There remains evidence that other cell types may also possess signaling mechanisms 
relevant to the development of TLO.  It has been demonstrated in ex-vivo studies that 
activated, but not naïve, T cells express LTα β1 2 (45).  LTβ expression is induced in B cells 
following antigen engagement and by chemokine (BLC) signaling, and it has been shown 
that the absence of LT expressing B lymphocytes results in the inability of isolated 
lymphoid follicles in the mucosal immune system to develop fully, suggesting that B cells 
participate in the development of mucosal lymphoid tissue (46).  Complicating matters is 
the differential expression of chemokines by immune cells depending on their specific 
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anatomic location.  It has been shown that while mature dendritic cells in lymph nodes 
strongly express the T cell chemoattractants SLC and ELC, mature dendritic cells residing 
in ectopic lymphoid tissue formed during chronic inflammation do not express these 
chemokines (47).  Further research aimed at clarifying the nature of the inducer cell during 
T cell mediated pathology is important to formulating approaches to modulate the 
formation of tertiary lymphoid tissue. 
Our data, which demonstrates that ectopic lymphoid tissue is sufficient to induce allograft 
rejection in an aly/aly mouse, support the theory that ectopic lymphoid tissue has the 
capacity to play a significant role in the alloimmune response.  Further characterization of 
the site of the alloimmune response may allow for more precise targeting of anti-rejection 
therapy, thus improving the quality of life for those who rely on the failure of the immune 
system to reject precious transplanted organs. 
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